rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy

Up to 30–50% of patients with locally advanced prostate cancer (PCa) undergoing radiotherapy (RT) experience biochemical recurrence (BCR). The immune system affects the RT response. Immunogenetics could define new biomarkers for personalization of PCa patients’ treatment. The aim of this study is to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zanusso, Chiara, Dreussi, Eva, Bortolus, Roberto, Romualdi, Chiara, Gagno, Sara, De Mattia, Elena, Romanato, Loredana, Sartor, Franca, Quartuccio, Luca, Cecchin, Erika, Toffoli, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539607/
https://www.ncbi.nlm.nih.gov/pubmed/31035590
http://dx.doi.org/10.3390/ijms20092082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539607/
https://www.ncbi.nlm.nih.gov/pubmed/31035590
http://dx.doi.org/10.3390/ijms20092082

Ejemplares similares